<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415792</url>
  </required_header>
  <id_info>
    <org_study_id>arvekap vs pregnyl</org_study_id>
    <nct_id>NCT00415792</nct_id>
  </id_info>
  <brief_title>Comparison Between hCG and GnRH Agonist for Ovulation Induction in Patients With High Response to IVF Drugs</brief_title>
  <official_title>Administration of Human Chorionic Gonadotropin (hCG) Versus Gonadotropin Releasing Hormone (GnRH) Agonist for Ovulation Induction in Hyper-Responder Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eugonia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eugonia</source>
  <brief_summary>
    <textblock>
      hCG and GnRH agonist can be used to induce final oocyte maturation and ovulation in IVF
      cycles. These two approaches will be compared in this study in terms of pregnancy rates and
      embryological data using patients with hyper-response to IVF drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      hCG is commonly used for the substitution of the endogenous LH surge to induce oocyte
      maturation and ovulation induction in ovarian hyperstimulation protocols for in vitro
      fertilization (IVF). However, hCG is related to the occurrence of the ovarian
      hyperstimulation syndrome (OHSS), a potentially life-threatening complication and
      hyper-responding patients are particularly in high risk. An alternative to exogenous hCG is
      the administration of a GnRH agonist inducing an endogenous rise in both LH and FSH levels
      due to the initial flare effect.

      Comparisons: Pregnancy rates and embryological data will be compared from hyper-responding
      patients receiving either GnRH agonist (Arvekap) or hCG (Pregnyl) for ovulatrion induction
      following a GnRH antagonist treatment cycle.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2003</start_date>
  <completion_date>July 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy per embryo transfer</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy per embryo transfer</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy per embryo transfer</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryological data</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Infertility</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arvekap, Pregnyl</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hyper-responder patients (&gt;20 oocytes retrieved)

        Exclusion Criteria:

          -  Normal responders

          -  Poor responders

          -  PCOS
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tryfon Lainas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eugonia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eugonia</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2006 Mar-Apr;12(2):159-68. Epub 2005 Oct 27. Review.</citation>
    <PMID>16254001</PMID>
  </reference>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2006</study_first_submitted>
  <study_first_submitted_qc>December 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2006</study_first_posted>
  <last_update_submitted>January 4, 2007</last_update_submitted>
  <last_update_submitted_qc>January 4, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2007</last_update_posted>
  <keyword>Ovulation induction</keyword>
  <keyword>hCG</keyword>
  <keyword>GnRH agonist</keyword>
  <keyword>hyper-responders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

